Barbara Savoldo, MD, PhD, and Gianpietro Dotti, MD, have established a fund to develop a CAR-T therapy for glioblastoma in honor of Savoldo’s sister, Sonia.
As part of a study led by Matthew Foster, MD, the advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia.
The European Medicines Agency granted priority medicines designation to Tessa Therapeutics’ CD30 targeted CAR-T therapy for patients with relapsed or refractory Hodgkin lymphoma.
CAR-T therapy has proven effective for some blood cancers. New research by Jonathan S. Serody, MD, and colleagues suggests ways to use it effectively to attack solid tumors.